Nomifensine in parkinsonism.

Nomifensine: effect in Parkinsonian patients not receiving levodopa.

A clinical trial using the anti-depressant nomifensine in Parkinsonism is reported. Eighteen subjects not receiving levodopa participated. The drug had a small, but significant anti-Parkinsonian effect. No troublesome side effects were encountered. In the treatment of Parkinsonism, nomifensine may be considered as an alternative to amantadine or anticholinergics, especially where depression is ...

Effect of nomifensine on anacoccygeus contraction induced by noradrenaline and electrical stimulation

  Nomifensine, an antidepressant agent, competitively inhibits dopamine uptake in the caudate-putamen and nucleus accumbens and binds to both dopaminergic and noradrenergic reuptake sites in the striatum and thalamus. In this study the effect of nomifensine on anacoccygeus contraction induced by noradrenaline and electrical stimulation was investigated in rats and compared to the effect of phen...

Effects of nomifensine (HOE 984) upon psychomotor activity and intracranial self-stimulation in the rat.

The effects of nomifensine maleate (HOE 984) were evaluated using two behavioral tasks. The drug produced dose related increases in both psychomotor activity and operant responding for brain stimulation reward. These results may point to possible psychostimulant properties for the drug.

Relationships to Nomifensine Bioactivation Mechanisms

Estrogen agonist genistein differentially influences the cognitive and motor disorders in an ovariectomized animal model of Parkinsonism

Objective(s): Parkinson's disease (PD) is a progressive neurological disorder associated with motor disabilities and cognitive dysfunction as well. Evidence indicates that PD occurs less frequently in women than men, confirming a role for steroid hormones in protection of dopaminergic nigrostriatal neurons. It is reported that soy genistein, an estrogen agonist phytoestrogen, display neuroprote...